image text translation
‘2 billion won per session’ for rare disease drugs
SMA completed for the first patient in Korea
Entered 2022.08.17. 7.07 am
Reporter Kim Jan-di >
71
71
c)) go
[3
24-month-old spinal muscular atrophy pediatric patient
At Seoul National University Hospital
Health insurance will be applied starting this month, maximum patient burden
5.98 million won
(Seoul-Yonhap News) ‘JUL’, a gene therapy for spinal muscular atrophy
The first patient to receive Lensma’s dose is a young child. 2022.08.17. [Seoul National University
Provided by hospital. Resale and DB prohibited]
(Seoul-Yonhap News) Reporter Jandi Kim
=
The drug price is 2 billion won.
‘Zlensma’, an ultra-expensive rare disease treatment
This is the first case of Nayongda being administered to a patient in Korea.
According to the pharmaceutical industry on the 17th, the previous afternoon, Seoul National University
Jonghee Chae, Director of the Rare Disease Center at the Hospital (Department of Clinical Genomic Medicine)
Led by a professor of pediatrics and adolescents, a 24-month-old
Zlens Maga for pediatric patients with spinal muscular atrophy (SMA)
administered
Medical insurance is applied, so it costs 6 million won.